Stifel Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Neutral 56.6%

Neg 0% Neu 56.6% Pos 0%

Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $45.